Hans van Houte, Chief Financial Officer at Nurix Therapeutics, Inc. (NRIX), sold 13,624 shares at $10.02 ($137K) on 2024-02-16, disclosed to the SEC on 2024-02-16.
Scheduled sale ($137k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.02 | 6,812 | $68K | 50.0% |
| 2 | $10.02 | 6,812 | $68K | 50.0% |
| Total | $10.02 avg | 13,624 | $137K | 100% |
| Filing → |
| NRIX | SELL | 2026-05-05 | $233K | — | Filing → |
| NRIX | SELL | 2026-04-30 | $40K | — | Filing → |
| NRIX | SELL | 2026-01-30 | $122K | — | Filing → |